The QualityStocks Daily Thursday, October 19th, 2023

Today's Top 3 Investment Newsletters

QualityStocks(ICU) $1.1900 +54.35%

MarketClub Analysis(MTC) $2.0600 +51.47%

Schaeffer's(LNN) $122.5800 +14.65%

The QualityStocks Daily Stock List

OZOP Energy Solutions (OZSC)

QualityStocks, MarketClub Analysis and InvestorPlace reported earlier on OZOP Energy Solutions (OZSC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OZOP Energy Solutions Inc. (OTC: OZSC) is focused on the design, manufacture and distribution of power electronics and endoscopic instruments.

The firm invents and develops power supplies, converters, inverters and ultra-high power chargers for various applications in the maritime, aircraft ground support, heavy industrial and defense sectors. OZOP Energy Solutions Inc. serves consumers across the globe.

The firm, which was known as OZOP Surgical Corp before changing its name, has its headquarters in Warwick, New York. OZOP Energy Solutions Inc. was established on July 17, 2015 and operates through the Hong Kong and United States geographical segments.

OZOP Energy Solutions also provides surgical devices, instrumentation and implants, which focus on neurological, spine and pain management specialties and procedures. The firm’s AC (alternating current) and DC (direct current) power supplies, which are available in ratings from 5KW (kilowatt) to 20 MW (megawatt), are utilized in multi-pulse silicon control rectifier, insulated gated bipolar transistor design. They provide low output noise, precise regulation, low ripple and also help achieve efficiency. The firm also offers a frequency converter for any military, industrial or commercial application with power ranges from 4KVA to 500 KVA (kilovolt-ampere). This is in addition to providing 400 hertz aircraft ground support equipment and manufacturing all types of power inverters, including electrostatic precipitators, power transmissions, solar cell power stations, AC/AC inverters, DC/AC inverters and DC/DC inverters.

OZOP Energy Solutions Inc. recently announced that they’d be developing the first contract energy systems for non-grid solutions. This move aligns with the firm’s expansion plan and with energy use in the U.S. set to increase significantly, the energy production industry is bound to need help in meeting the population’s needs, which is where the firm is set to gain hefty returns for its shareholders.

OZOP Energy Solutions (OZSC), closed Thursday's trading session at $0.0027, up 42.1053%, on 55,893,313 volume. The average volume for the last 3 months is 8.671M and the stock's 52-week low/high is $0.0018/$0.0117.

Outlook Therapeutics (OTLK)

MarketBeat, QualityStocks, StockMarketWatch, INO Market Report, BUYINS.NET, TopPennyStockMovers, The Online Investor, StreetInsider, Small Cap Firm, PoliticsAndMyPortfolio, MarketClub Analysis, InvestorsUnderground and InvestorPlace reported earlier on Outlook Therapeutics (OTLK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Outlook Therapeutics Inc. (NASDAQ: OTLK) (FRA: 41ON) is a late clinical-stage biopharmaceutical firm that is engaged in the development and commercialization of monoclonal antibodies for different ophthalmic indications.

The firm has its headquarters in Iselin, New Jersey and was incorporated in 2010, on January 5th by Pankaj Mohan. Prior to its name change in November 2018, the firm was known as Oncobiologics Inc. It serves consumers in the United States.

The company uses its Biosymphony biosimilars business models to achieve technical excellence and accelerated development, to help create affordable medications for patients around the globe. It is party to collaboration and license agreements with Zhejiang Huahai Pharmaceuticals Co. Ltd, BioLexis Pte. Ltd., Laboratorios Liomont S.A. de C.V., and IPCA Laboratories Ltd.

The enterprise is advancing a pipeline of 11 biosimilar products. Its product pipeline comprises of an ophthalmic formulation of bevacizumab dubbed ONS-5010, which will be administered as an intravitreal injection. The formulation is undergoing a phase 3 clinical trial evaluating its effectiveness in treating retina ailments like wet age related macular degeneration. Bevacizumab is a humanized, full-length anti-vascular endothelial growth factor (VEGF) recombinant monoclonal antibody which inhibits VEGF and related angiogenic activity. Its ONS-5010

The firm is focused on creating shareholder value and building momentum that will help bring the first ophthalmic bevacizumab formulation to be approved by the FDA to the retina space. Having released promising results from its latest pivotal study, the firm is continuing its shift towards commercialization.

Outlook Therapeutics (OTLK), closed Thursday's trading session at $0.66, up 39.9194%, on 125,683,362 volume. The average volume for the last 3 months is 312,043 and the stock's 52-week low/high is $0.2002/$2.03.

CK Hutchison (CKHUY)

DividendStocks, TopStockAnalysts, MarketBeat, InvestorPlace, StreetAuthority Daily, MarketClub Analysis and Daily Profit reported earlier on CK Hutchison (CKHUY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CK Hutchison Holdings Limited (OTC: CKHUY) (HKG: 0001) is an investment holding firm that operates in ports and related services, infrastructure, retail and telecommunications businesses.

The firm has its headquarters in Central, Hong Kong and was incorporated in 1828. It operates as part of the conglomerates industry, under the industrials sector. The firm serves consumers globally, with a focus on those in the United States.

The enterprise invests in, develops and operates ports, which operate 293 berths in 51 ports spanning 25 countries. It also offers logistics and transportation-related services, such as river trade, cruise ship terminals, distribution centers and ship repair facilities; and operates retail brands with stores that provide personal care, food and fine wines, health and beauty products, consumer electronics, and electrical appliances. The enterprise also operates supermarkets; manufactures and distributes bottled water and other beverages under the Watsons Water and Mr. Juicy brands; and invests in transportation infrastructure, energy infrastructure, water infrastructure, waste management, waste-to-energy, household infrastructure, and other infrastructure-related businesses. In addition to this, the enterprise offers mobile telecommunications and data services; and provides marine construction and ship repair yard, water supply and sewerage, general engineering and tug operations, electricity generation and distribution, gas distribution, and aircraft maintenance services. Furthermore, it leases rolling stocks.

The company, which merged its UK mobile operations with Vodafone earlier in the year, remains committed to transforming mobile services for its consumers and extending its overall consumer reach. This may open the company up to new opportunities for business and help create additional value for its shareholders.

CK Hutchison (CKHUY), closed Thursday's trading session at $5.05, off by 1.5595%, on 193,451 volume. The average volume for the last 3 months is 28,724 and the stock's 52-week low/high is $4.81/$6.89.

Ajia Innogroup (AJIA)

We reported earlier on Ajia Innogroup (AJIA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ajia Innogroup Holdings Ltd (OTC: AJIA) is an all-in-one point-of-sale and restaurant management platform.

The firm has its headquarters in Las Vegas, Nevada and was incorporated in 2014, on March 19th by Tam Yiu Chuen. Prior to its name change in March 2018, the firm was known as Wiigi4you Inc. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in the People’s Republic of China.

The company’s subsidiaries include Ajia Creative Holdings Limited, which is focused on the provision of food and beverage sales system setup and maintenance service; Splendor Radiant Limited, which is engaged in the investment holding business; Union Passenger Limited, which is engaged in the provision of catering member service solutions and service platform; and Ajia Corporate Systems Architecture Solution Limited, which is engaged in the provision of money lending, insurance brokerage and business development trustee service.

The enterprise’s cloud-based system has been built specifically for restaurants. It provides advanced functionality including tableside ordering, quick menu modifications, real-time enterprise reporting, online ordering, and labor management on an easy-to-use interface. It is also pursuing the business of having self-help photo kiosks, which are implemented at convenient locations, such as shopping malls and buildings near subway stations, to attract customers to use the service of photo printing.

The firm remains focused on expanding its market via collaboration with trust companies in the United States and Canada and generating additional value for its stakeholders.

Ajia Innogroup (AJIA), closed Thursday's trading session at $0.0186, even for the day. The average volume for the last 3 months is 33,748 and the stock's 52-week low/high is $0.0014/$0.50.

Chakana Copper (CHKKF)

We reported earlier on Chakana Copper (CHKKF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Chakana Copper Corp. (OTCQB: CHKKF) (CVE: PERU) (FRA: 1ZX) is a minerals exploration firm that is focused on acquiring, exploring for and developing mineral properties.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2011, on May 2nd. It operates as part of the other precious metals and mining industry, under the basic materials sector. The firm primarily serves consumers in Canada and Peru.

The company primarily explores mineral properties with prospects for copper, gold, and silver. It focuses on testing breccia pipes to determine if they host economic mineralization. Its projects include tourmaline breccia pipes and Soledad. The company’s wholly-owned subsidiary is Chakana Resources S.A.C.

The enterprise holds an option to acquire a 100% interest in the Soledad project located in Central Peru. This project is notable for the high-grade copper-gold-silver mineralization that is hosted in tourmaline breccia pipes. The Soledad project is located in Ancash province of central Peru, roughly 260km north-northwest of Lima and 35km south of Barrick’s Pierina mine. The project is part of the Ticapampa-Aija Mining District in the Cordillera Negra. The enterprise also holds an option interest in other mineral concessions owned by Minera Barrick Misquichilca S.A. Its other interests include the Mega-Gold intrusion-hosted copper-gold zone and the La Joya high-sulfidation epithermal gold-silver zone.

The firm recently received final approval to drill numerous targets defined in a portion of the southern-half of Chakana's Soledad project within the Miocene mineral belt, a move that brings them closer to production and may help generate significant value for its shareholders if efforts are successful.

Chakana Copper (CHKKF), closed Thursday's trading session at $0.029, up 1.0453%, on 116,100 volume. The average volume for the last 3 months is 17,653 and the stock's 52-week low/high is $0.0287/$0.08844.

Cascadero Copper Corporation (CCEDF)

We reported earlier on Cascadero Copper Corporation (CCEDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cascadero Copper Corporation (OTC: CCEDF) (CVE: CCD) (FRA: C5C) is an integrated mineral exploration and development business that is focused on acquiring, exploring for and developing mineral properties.

The firm has its headquarters in North Vancouver, Canada and was incorporated in 2003, on October 30th. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm primarily serves clients in Argentina. It has offices in North Vancouver, BC and Salta City in the Province of Salta, Republic of Argentina.

The company explores for cesium, silver, zinc, lead, gold, uranium, copper, tellurium, tin, molybdenum, iron and rubidium ores. It holds interests in 27 mineral properties located in the northern area of the Argentine Puna (primarily in the Province of Salta). The company’s properties include Amarillo, Amarillo Norte, Taron Group, Santa Rosa Group, El Oculto Group, Incamayo Norte, Ochaqui Silver, TacaTaca Group and Viejo Campo. The Amarillo Norte property includes sediment-hosted cesium-silver deposits. The El Oculto group is comprised of the El Oculto, Centauro, Cerro Lari I and Cerro Lari II properties. The Ochaqui property is located at the eastern edge of the Argentine Puna about 100km west of Salta city and roughly 10km south of the Incamayo property. The Incamayo Norte property is located about 100km west of the city of Salta, in the Sierra de Cachi portion of the Nevados de Palermo Mountain Range.

The firm, which recently announced the results of its latest shareholder AGM, remains focused on advancing its exploration and drilling efforts at its properties and generating additional value for its shareholders.

Cascadero Copper Corporation (CCEDF), closed Thursday's trading session at $0.0028, even for the day. The average volume for the last 3 months is 49,293 and the stock's 52-week low/high is $0.0015/$0.03.

Ascendant Resources (ASDRF)

Pennystockmania and PennyPickGains reported earlier on Ascendant Resources (ASDRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ascendant Resources Inc. (OTCQB: ASDRF) (TSE: ASND) (FRA: 2D9) is a mining firm focused on exploring for and developing mineral properties.

The firm has its headquarters in Toronto, Canada and was incorporated in 2006, on August 17th by Stephen M. Shefsky, Chris Buncic, Thomas J. Loch, Clifford David Hale-Sanders and Mark Peter Brennan. Prior to its name change in December 2016, the firm was known as Morumbi Resources Inc. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm mainly serves consumers in Canada.

The company primarily explores for zinc, copper, lead, tin, silver and gold, among other metals. It holds 80% interest in the Lagoa Salgada volcanogenic massive sulfide (VMS) project through its position in Redcorp Empreendimentos Mineiros Lda subsidiary. This project is located within the north-western section of the prolific Iberian Pyrite Belt in Portugal, about 80km southeast of Lisbon. The project is comprised of a single exploration permit that covers an area of roughly 10,700 hectares. The project represents an early-stage, potentially high-grade, polymetallic zinc-lead-copper exploration opportunity. The Lagoa Salgada project comprises two known deposits, the Venda Nova North, and South Deposits. The Lagoa Salgada north deposit is comprised of gossan (Gos) mineralization. The Lagoa Salgada south deposit comprises copper-rich stringer/ fissure/stockwork and remobilized mineralization.

The firm, which recently announced that it had commenced the tender phase for the Mandated Lead Arranger of its Export Credit Agency project financing program, remains committed to completing project financing and developing its highly prospective Lagoa Salgada VMS project.

Ascendant Resources (ASDRF), closed Thursday's trading session at $0.0601, even for the day. The average volume for the last 3 months is 301,390 and the stock's 52-week low/high is $0.05905/$0.21658.

TerrAscend Corp. (TSNDF)

QualityStocks, InvestorPlace and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eligible Canadian marijuana cultivators and processors can seek financial support through the new Sustainable Canadian Agricultural Partnership program (Suitable CAP), valued at C$3.5 billion ($2.6 billion). The program could bring relief to the smaller players in Canada’s marijuana industry that have been grappling with continuous deflationary pressures and intense competition, coupled with limited access to funds from private-sector lenders.

The support provided by the Sustainable CAP will be an addition to various other federal funding sources that Canadian marijuana companies have been leveraging. These include the National Research Council Canada (NRC), the Industrial Research Assistance Program (IRAP), and the Scientific Research and Experimental Development (SR&ED) program. The Sustainable CAP program is a collaborative effort between the federal and provincial governments under the umbrella of Agriculture and Agri-Food Canada, the governmental department responsible for agriculture.

George Smitherman, CEO of the Canada Cannabis Council, expressed satisfaction with the initiative, describing it as a significant shift in the agricultural department’s acknowledgment of cannabis as a value-added agricultural product. The council serves as the national industry association, representing the interests of numerous licensed processors and producers in the country.

Replacing the Canadian Agricultural Partnership (CAP), the Sustainable CAP program will be operational from April 1, 2023, until March 31, 2028. It comprises a C$1 billion allocation for activities and programs directly managed by the federal government, with an additional C$2.5 billion committed to cost-shared programs overseen by territories and provinces.

Until now, no marijuana companies have been involved in federal projects under the Sustainable CAP.

One of the federal programs of Sustainable CAP that marijuana-related enterprises may qualify for is the AgriAssurance Program, which includes two segments: the Small and Medium-Sized Enterprise (SME) and the National Industry Association (NIA). The NIA segment finances projects at the national level to facilitate the industry in creating and adopting tools, standards and systems that bolster safety and health claims pertaining to agricultural and agri-food Canada products. The SME segment aims to aid for-profit SMEs in executing assurance projects that cater to market and regulatory prerequisites.

Cannabis businesses are eligible to seek funding from both the AgriScience and AgriInnovate programs, provided that their proposals align with the program’s objectives, they possess valid licenses and their activities are consistent with their Health Canada licenses.

Applications for Sustainable CAP programs are evaluated on an individual basis, contingent on the specific program’s funding criteria. Additionally, applicants must already possess the requisite licenses and comply with federal and provincial laws and regulations, including the Cannabis Act.

Licensed operators such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) could be pleased by these developments that show that the cannabis industry is now being embraced as any other industry that needs to be supported in any way possible so that it can thrive not just nationally but on a global scale too.

TerrAscend Corp. (TSNDF), closed Thursday's trading session at $1.88, up 2.0353%, on 95,362 volume. The average volume for the last 3 months is 558,717 and the stock's 52-week low/high is $1.00/$2.50.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, Dynamic Wealth Report, StreetInsider, MarketClub Analysis, Uncommon Wisdom, Marketbeat.com, CRWEWallStreet, PennyToBuck, CRWEPicks, InsiderTrades, CRWEFinance, BestOtc, DrStockPick, PennyOmega, Schaeffer's, Small Caps, StockHotTips, TraderPower, Awareness Stocks, StockOodles, Street Insider, The Street, TopPennyStockMovers, Broad Street and ProTrader reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A surge of psychedelic research has significantly increased the public appeal of psychedelics in recent years. Researchers have discovered that several psychedelics have the potential to treat various mental-health disorders safely and effectively, making them possible alternatives for conventional mental-health treatments.

Psychedelics such as LSD, psilocybin, ayahuasca and mescaline have shown significant potential against conditions such as anxiety, depression and post-traumatic stress disorder (PTSD), seeming to offer long-term relief with minimal adverse side effects and at relatively low doses.

However, we still don’t fully understand how psychedelic experiences impact the brain and lead to profound realizations in psychedelic users. While scientists have reason to believe that psychedelics work by interacting with receptors such as the serotonin 2A receptor (5-HT2AR), the underlying mechanisms that allow them to deliver their benefits still aren’t fully understood.

Researchers are now looking into the possibility that personality plays a larger role in psychedelic experiences than previously thought. Personality traits affect how we interact with our feelings, thoughts, relationships and the world at large, after all, and some scientists posit that our traits may also shape how we react to psychedelics.

Genes are partly responsible for some personality traits while others develop in response to experiences. These traits tend to settle as we reach adulthood but can go through small gradual changes over time. Psychedelics can disrupt entrenched personality traits and change how people perceive themselves and the world around them, resulting in profound realizations that can cause long-lasting personality changes.

Their ability to disrupt previously held perceptions, open up people’s minds and help individuals gain different insights into their emotions allows psychedelics to treat conditions such as major depressive disorder. As such, it makes sense that personality traits including agreeableness, extraversion, conscientiousness, neuroticism and openness should affect psychedelic experiences.

Interestingly, researchers found that personality can affect an individual’s response to a psilocybin journey. Findings published in the “Journal of Psychoactive Drugs reveal that individuals with high levels of openness were more likely to have psychedelic experiences characterized by contact with transcendent forces and nonordinary beings as well as love and inner visions. Furthermore, people who scored high in extraversion had feelings of deeper connection to other people and were unlikely to contact non-ordinary beings while under the influence of psychedelics.

High levels of neuroticism increased one’s chances of having a bad psychedelic trip, highly emotional people had little chance of experiencing fear during their experiences, and risk takers had a higher chance of experiencing ego death. The findings also indicate that psychedelics can decrease neuroticism and increase extraversion, conscientiousness and openness.

Enterprises such as atai Life Sciences N.V. (NASDAQ: ATAI) could also help the world understand the more specific ways in which psychedelics interact with different categories of patients in order to deliver therapeutic benefits, and how dosing can be tweaked to address individual needs or differences.

atai Life Sciences N.V. (ATAI), closed Thursday's trading session at $1.29, off by 5.1471%, on 562,119 volume. The average volume for the last 3 months is 394,876 and the stock's 52-week low/high is $1.14/$3.65.

Arch Resources Inc. (ARCH)

The Online Investor, InvestorPlace, QualityStocks, Zacks, MarketBeat, DividendStocks, MarketClub Analysis, Investors Alley, TradersPro, Schaeffer's, Kiplinger Today, The Street, Daily Wealth, MiningNewsWire, StreetAuthority Daily, Cabot Wealth, Daily Trade Alert, Uncommon Wisdom, Early Bird, FreeRealTime, Investing Daily, Trades Of The Day, Barchart, StreetInsider, Smart Investing Society and InvestorGuide reported earlier on Arch Resources Inc. (ARCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A ground-breaking project in the English town of Gateshead is using abandoned coal mines to provide winter heating to hundreds of businesses and homes. The former coal community has been drawing heat from the warm water filling the labyrinth of old coal mining tunnels for the last six months.

With an estimated one-quarter of homes in the United Kingdom sitting atop networks of coal tunnels, the pilot project shows that using abandoned coal mines for heating could be a feasible option for millions of UK residences. The project provides a means for the UK to leverage coal mines that are otherwise useless while providing homes with much-needed heating amid energy shortages and soaring prices.

John Elroy, the Gateshead Cabinet member for the environment and transport, says that while the town may have a history of dabbling in dirty energy, it is now a leader in clean-energy generation using the very mines used to produce coal.

Around 150,000 abandoned mining shafts and 9,652 square miles of disused tunnels and mines in the UK have become flooded with water after decades of disuse. This water constantly draws heat from the earth and could prove to be one of the UK’s largest sources of underused green energy. An interactive map of disused coal mines from the UK Coal Authority shows that the water becomes more hot the deeper the mines go, reaching up to 45 degrees Celsius at depths of 0.6 miles.

While the water can mix with toxic compounds from subterranean rock and likely isn’t suitable for consumption, it can be a valuable thermal resource for homes and offices. The water is accessed through boreholes that raise it to the surface before being directed and compressed by heat pumps and extractors, which raises the temperatures to much higher levels. Pumps are used to distribute the heated water to buildings via heating networks where the heat is absorbed, and the now-cool water is redirected into the mining system for heating.

The coal authority’s head of heat and byproduct innovation Gareth Farr says flooded coal mines present a chance for the generation of a secure supply of low-carbon heat for people living or employed in buildings constructed on abandoned coalfields. Farr notes that with millions of Britons currently living on disused coal fields, the flooded underground tunnels have significant potential as sources of heat for multitudes of UK residents.

Using the abandoned coal mines for heating could also prove to be an economic boost for communities that were affected by the closure of deep coal mines in the 1980s.

The Gateshead project is an indicator that the places where extractors such as Arch Resources Inc. (NYSE: ARCH) have operations that can eventually be put to good use once coal mining is no longer viable.

Arch Resources Inc. (ARCH), closed Thursday's trading session at $152.25, off by 2.8398%, on 379,421 volume. The average volume for the last 3 months is 4.904M and the stock's 52-week low/high is $102.42/$175.10.

SNDL Inc. (SNDL)

InvestorPlace, Schaeffer's, StockEarnings, StocksEarning, QualityStocks, MarketBeat, Trades Of The Day, Daily Trade Alert, BUYINS.NET, The Street, Kiplinger Today, The Online Investor, StreetInsider, Early Bird, CNBC Breaking News, FreeRealTime, Investopedia, MarketClub Analysis, StockMarketWatch and MarketClub reported earlier on SNDL Inc. (SNDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Several months after Minnesota Governor Tim Walz signed a recreational cannabis legalization measure into law and nearly two months after the legislation took effect, the state has seen a significant increase in demand for marijuana classes. Minnesota is a relatively late entrant into the recreational cannabis game, but Minnesotans proved that they overwhelmingly supported legalization via a ballot vote, and they are now eager to learn as much as they can about the often-controversial plant.

According to Minnesota Cannabis College president Tanner Berris, demand for marijuana classes across the state is huge as many residents are itching to tap into the recently launched recreational cannabis industry. Berris says the college has been receiving calls every day, every hour from people who would like to become part of the cannabis industry by either opening a cannabis business or getting a job in the nascent industry.

Although the college’s marijuana program isn’t accredited, the nonprofit has been able to expand from its hemp roots to recreational cannabis now that the state has legalized adult-use marijuana. The college’s goal is now to provide support to entrepreneurs interested in joining the cannabis sector and provide them with the training they will need to flourish in the industry. The school will soon start to offer classes on cannabis cultivation, business management, and “budtending” training to people who want to work in retail cannabis stores.

Since Minnesota’s recreational cannabis law won’t allow the launch of retail marijuana dispensaries until 2025 (with the exception of some tribal nations), interested entrepreneurs have plenty of time to learn about cannabis commerce before official sales commence.

In the meantime, state law currently allows Minnesotans to cultivate up to eight cannabis plants at home.

Although the Minnesota Cannabis College began offering cannabis cultivation classes in reaction to home cultivation laws, the nonprofit is more interested in providing business-related cannabis knowledge. Berris says the most surprising thing has been the number of Minnesotans who have expressed interest in launching their own business. This includes people who use cannabis either sporadically or regularly as well as people who don’t use cannabis but are entrepreneurs who noticed a business opportunity in Minnesota’s burgeoning cannabis sector and are looking for industry-specific information before taking the plunge. Berris says all of the cannabis classes at the nonprofit are full.

Minnesotans interested in an online cannabis education certificate can also head to St. Cloud State University for programs that cover cannabis healthcare and medicine, cannabis compliance and risk management, cannabis agriculture and horticulture, and business of cannabis.

This explosive interest in Minnesota could be signaling to entities operating elsewhere, such as SNDL Inc. (NASDAQ: SNDL), that the cannabis industry still has plenty of room for growth, and any policy changes at the federal level will probably take this growth to a whole new level, bringing massive opportunities to sector players.

SNDL Inc. (SNDL), closed Thursday's trading session at $1.49, off by 1.3245%, on 2,317,371 volume. The average volume for the last 3 months is 2,600 and the stock's 52-week low/high is $1.25/$3.36.

EF Hutton Acquisition Corp (EFHT)

We reported earlier on EF Hutton Acquisition Corp (EFHT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

EF Hutton Acquisition Corporation I (NASDAQ: EFHT), a special purpose acquisition company formed by affiliates of EF Hutton, a division of Benchmark Investments LLC, has entered into a definitive securities purchase agreement (“SPA”) with an institutional investor. The agreement outlines the issue of a senior secured convertible note for $15,819,209 in principal. According to the announcement, the note will be issued in connection with the closing of a proposed business combination with Humble Imports Inc. d/b/a ECD Auto Design. ECD Auto is a leading manufacturer of restored and modified Land Rover Defenders. The note calls for the company to receive proceeds of more than $13 million before the payment of expenses. Terms of the note also include the accrual of interest at an annual rate equal to the prime interest rate plus 5% per annum; the interest is payable monthly in cash or in securities of the company, depending on the company’s preference, provided certain conditions are met. “We believe that the net proceeds from the SPA will provide ECD Auto with sufficient capital to achieve the next steps in growing its business organically through a combination of increased volume, higher average selling prices and a broader range of models for customers to choose from,” said EF Hutton Acquisition Corporation I chair and CEO Ben Piggott in the press release.

To view the full press release, visit https://ibn.fm/ISlXq

About EF Hutton Acquisition Corporation I

EF Hutton Acquisition Corporation I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

EF Hutton Acquisition Corp (EFHT), closed Thursday's trading session at $10.7, up 0.469484%, on 1,030 volume. The average volume for the last 3 months is 136,281 and the stock's 52-week low/high is $9.98/$11.37.

The QualityStocks Company Corner

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month's Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO John Climaco is scheduled to participate in a live moderated webcast during the conference; the webcast is slated to start at 4 p.m. ET. The distinctive conference provides a unique opportunity for members of the investment community to ask questions directly to leaders of specific companies during the live event. According to the announcement, executive answer as many questions as possible during the interactive webcast. A replay of Climaco's "Ask the CEO" presentation will be available on the company website following the event.

To view the life webcast, visit https://ibn.fm/tQsBx

To view the full press release, visit https://ibn.fm/0bntZ

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $1.98, up 11.236%, on 131,555 volume. The average volume for the last 3 months is 81,181 and the stock's 52-week low/high is $0.6105/$6.597.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria, a global innovator in drug delivery platforms, recently announced that it had entered into a securities purchase agreement with a single health-focused institutional investor

The agreement is for the purchase of 1,618,330 shares of common stock at $0.97 per share, with gross proceeds amounting to approximately $1.6 million

The raised funds will be integral to Lexaria advancing its operations, inching it closer to FDA approval for its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension

It will also help assert Lexaria's position as a leader in the market, even as it pushes the envelope in terms of research and development of its revolutionary DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, raised approximately $1.6 million from its latest round of investment in what will mark a significant milestone for the company. In September 2023, the company announced that it had entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock at $0.97 per share. Maxim Group LLC acted as the sole placement agent in connection with the offering (https://cnw.fm/TNjLB).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $1.08, up 8.0216%, on 78,822 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.597/$.

Recent News

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF)

The QualityStocks Daily Newsletter would like to spotlight Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF).

Canadian mineral explorer Appia Rare Earths & Uranium is acquiring project sites with rare earth element ("REE") potential to help sustain American hemisphere independence in the REE supply chain

The People's Republic of China currently enjoys a near-monopoly over REE mining and production, leading Western nations to seek greater security for the metallic elements vital to modern computer technologies and the strong magnets used in them

Appia recently reported updated results from its drilling programs designed to identify the extent of REE mineralization at the company's project site in central Brazil, expressing excitement over the project's potential

The company is also exploring for REEs in Saskatchewan and Ontario, Canada, and recently completed an NI43-101 technical report on the Saskatchewan site

Mineral exploration company Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF) recently announced an update on its efforts to identify the extent of rare earth element REE-laden clays at a newly acquired project site in Brazil, expressing excitement over the promising results of exploration thus far.

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (REE) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.

Projects

PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (RC) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (HREEs) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (LREEs) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (SSE). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

  • Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
  • Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

Appia Rare Earths & Uranium Corp. (OTCQX: APAAF), closed Thursday's trading session at $0.17, up 17.0799%, on 321,335 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.075/$0.35685.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN's sustained effort to provide specialized content distribution via widespread syndication channels. Richard Clowater, president of GEMXX, joined the program to share insight into the company, beginning the interview expounding on a recent news release detailing why management feels GEMXX is currently undervalued.

"Since its inception, GEMXX has always looked for resource assets that are commercially viable. To date, we've acquired five properties, but only one of those properties has a partial assessment known as an S-K 1300, which is a report produced by a qualified professional. These reports offer comprehensive insights into mineral resources, reserves, exploration, outcome and the technical intricacies of a project. That being said, the report is not required to determine if a property is a good acquisition – if you have enough mining experience," Clowater said. "Prior to purchasing any resource asset, GEMXX completes due diligence and conducts resource confirmation estimates of its own. This includes but is not limited to core samples, trenching and bulk sampling. These preliminary test results, combined with our decades of mining experience, allow GEMXX to quickly estimate the resource at a high level and determine its commercial viability and the potential ROI for each property. But as a rule, the company does not add any resource to the balance sheet until it has been confirmed by an independent third-party professional. That is why we own four very large assets that do not appear on the balance sheet, thus undervaluing the company and the assets that it owns."

To view the full press release, visit https://ibn.fm/OtJX5

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Thursday's trading session at $0.06, up 16.9591%, on 19,068 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.023/$0.998.

Recent News

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

Electronic Servitor Publication Network (OTCQB: XESP), a digital engagement company and market disruptor that provides cutting-edge data analysis and intelligent technology, today announced that Eric Swann has joined XESP as a valued consultant. Swann brings over 35 years of experience investing in and working with both public and private markets. A founding partner of Leerink Swann, he has more recently dedicated his time to medical technology and life science companies working alongside entrepreneurial management teams with unique products in these dynamic industries. "As a proven leader with three decades of deep industry knowledge, Eric will enhance the team in refining our corporate strategy, elevating our market position, and aligning XESP with world-class channel partners and customers," said Peter Hager, CEO of XESP. "Our Digital Engagement Engine(TM), combined with our managed service offering, helps customers rapidly grow and effectively navigate in the ever-changing digital landscape and volatile industries. Eric is uniquely qualified to work directly with the C-suite executives to maximize results and returns while minimizing risk. We are excited to collaborate with Eric and leverage his results-oriented experience to drive value for our clients!"

To view the full press release, visit https://ibn.fm/54Slu

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.

Technology

Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by ReportLinker.com, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Thursday's trading session at $0.07, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.16.

Recent News

SOHM Inc. (OTC: SHMN)

The QualityStocks Daily Newsletter would like to spotlight SOHM Inc. (OTC: SHMN).

Generic drug manufacturer and distributor SOHM has completed the LOI process to acquire stem cell gene-editing technology ABBIE from CGA Intellectual Holdings Inc.

The company expects the technology to provide it with commercialization revenues as it builds a solution for gene-enhanced stem cells that can be used to treat a number of diseased organs, beginning with heart ailments

The edited-gene cells are expected to be used for in-human clinical trials by 2025, using a non-viral vector for inserting the genes into patients' bodies

SOHM believes the technology will provide it with a competitive advantage in a market expected to grow from current annual revenues of $5.3 billion to $10.8 billion by 2028

Global generic drug innovator SOHM (OTC: SHMN) is celebrating the fulfillment of its letter-of-intent to acquire a disruptive stem cell technology and patents from CGA Intellectual Holdings Inc., which will allow the company to create regenerative medicine and cosmeceutical products for commercialization during the next year.

SOHM Inc. (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills, California.

The company’s primary goal is to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier quality and keeping prices affordable. SOHM is dedicated to fully complying with all relevant regulatory prerequisites and upholding the most rigorous industry benchmarks, including the guidelines set forth by WHO-CGMP and USFDA.

Achievements and Milestones

SOHM is a recognized generic pharmaceutical manufacturer, with production and marketing of generic drugs covering all major treatment categories. SOHM also markets innovative formulations and packaging for various therapeutic segments, such as cosmeceuticals, nutraceuticals and OTC oral dosage formulations, with operations spanning India, the Philippines, Uganda, the U.S., the UK and the EU.

SOHM successfully launched a unique and innovative Salic-2 face wash, FōHM by SOHM, during the Oscar after party in Hollywood. The innovative Salic-2 offering in translucent gel form is marketed as an acne medication in the U.S. cosmeceutical market.

With proficiency in both manufacturing and marketing, SOHM stands out. The company holds licenses for producing over 300 products and has established distribution partnerships with firms in the United States, the Philippines and Uganda. Additionally, SOHM’s repertoire includes the launch of an innovative protein supplement, I-Prolec, featuring a distinct composition—a first-of-its-kind in India.

In 2012, SOHM gained recognition as “the most emerging company in the recent past” at the National Integrated Medical Association Conference. The company’s growth was underscored by its inclusion in the roster of ‘Fastest Growing Public Companies’ according to the Orange County Business Journal.

SOHM Today

SOHM brings all of its expertise and market knowledge toward a new vision. The company continues to develop, manufacture and market generic pharmaceutical drugs for various treatment categories. It offers its products in various dosage forms, including tablets and capsules, creams and topicals, ointments and liquids. The company also provides anti-arthritic/analgesics, dermatological drugs, gastrointestinal and respiratory drugs, biotechnology products, anesthetics, immunosuppressive agents and other various treatments. In addition, it offers a skincare line that includes dry dermatoses, mixed skin infection, acne vulgaris and seborrheic dermatitis products.

SOHM markets its products directly and through partner alliance agreements to drug wholesalers, mass merchandisers, chain drug stores and mail-order pharmacies primarily in the U.S. and has previously done business in the Far East, Africa and Southeast Asia. The company is working with its alliance partner in the African continent and Latin American countries.

SOHM has developed a comprehensive marketing strategy encompassing a diverse range of tactics to promote all products. SOHM uses the power of digital marketing channels, social media campaigns and targeted advertising to significantly enhance awareness and recognition of product offerings.

All distribution networks are strengthened through valuable partnerships. SOHM has gained access to the extensive U.S. market through a strategic alliance with different wholesalers catering to C-stores and retailers. The company has likewise partnered with a distribution firm that holds a remarkable network of more than 4,500 independent pharmacy accounts.

Additionally, a strong partnership with a prominent distribution network in New Jersey enables SOHM to facilitate nationwide distribution to big distribution houses, hospitals and retail chain stores which include but are not limited to Walmart, Publix, Sam’s and many more retail giants, thus extending the company’s market presence.

SOHM Long-Term

A report by Grand View Research estimated the global nutraceuticals market at $291.33 billion in 2022 and forecasts expansion at a compound annual growth rate (CAGR) of 9.4% from 2023 to 2030. The report states primary factors driving the market growth are preventive health care, increasing instances of lifestyle-related disorders, and rising consumer focus on health-promoting diets. Additionally, increasing consumer spending power in high-growth economies is projected to contribute to the growing demand for nutraceutical products.

Grand View valued the global NSAID market at $19.55 billion in 2021 and forecast it would expand to nearly $30 billion by 2030, marking a CAGR of 5.36% for the period. Projected growth is attributed to factors like the rising prevalence of chronic pain across the world, coupled with a growing global geriatric population. In addition, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs in treating headaches, migraine, toothaches and menstrual pain is expected to boost market growth.

Fortune Business Insights estimated that the global cosmeceuticals market was worth $54.57 billion in 2022 and projects the market will grow to a value of $96.23 billion by 2029, marking a CAGR of 8.4% during the forecast period. The report credits the projected growth to the prevalence of skin disorders around the world and the inclination of dermatologists to prescribe or recommend these products as compared to other treatments.

SOHM envisions a future where it evolves into a prominent global corporation, expanding its reach across international borders while upholding its fundamental core values. The company aspires to extend its export portfolio to encompass 11 countries, showcasing a robust international presence.

Aiming for financial stability, SOHM is committed to maintaining sufficient working capital to support its growth endeavors. The company’s forward trajectory involves strategic collaborations, mergers with diverse brands and a focused approach to business expansion through vertical integration and a balanced mix of organic and inorganic strategies.

In this pursuit, SOHM is dedicated to establishing its proprietary network of partners within the over the counter (OTC) sector. Furthermore, the company seeks heightened recognition within crucial therapeutic domains, including oncology, HIV, cardiovascular health, diabetes care and skincare-dermatology, solidifying its prominent standing in these pivotal segments.

Management Team

Baron Night is CEO, President, and Director at SOHM Inc. He has over 40 years of experience in various industries with extensive contacts in emerging markets. His leadership and track record are great assets to the company as SOHM continues to strengthen its position and develop large-scale distribution of generic drug lines.

David Aguliar, Ph.D., is the COO of SOHM. He has 22 years of experience in the pharmaceutical industry, including multiple research positions and scientific publications. He has an extensive background in pharmaceutical Chemistry Manufacturing and Controls (CMC), as well as quality assurance experience in preclinical and Investigational New Drug (IND) application filings of allogeneic cell-based therapies. He has a deep understanding of regulatory and clinical pathways, coupled with an extensive scientific and technical background in the fields of pharmaceuticals, biopharmaceuticals and gene editing tools research.

Dr. Krishna Bhat, MD PHD, FACC, has a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which was awarded in recognition of his commitment to excellence in the field of Cardiovascular Care through his leadership as an outstanding physician, researcher, and educator. He is also a recipient of the Miles Canada Fellowship Award and the J. Louis Levesque Fellowship Award from Montreal Heart Institute in Montreal, Canada.

Dewey Rushing is a Senior Compliance Remediation and Quality Professional with over 30 years of experience in Quality Assurance and cGMP Compliance for products regulated by the U.S. Food and Drug Administration (FDA). He served as a trained Consumer Safety Investigator at the FDA and Instructor at the Los Angeles District. He has in-depth knowledge in technology transfer of biologics and pharmaceutical products, as well as validation of manufacturing equipment, facility cleaning and critical utility systems maintenance. He has an extensive background in auditing GMP facilities, implementing quality systems and performing gap assessments of manufacturing processes and facilities. He has also directed remediation projects in response to federal compliance audit observations.

Sowmya Jacob, MBA-PGP, possesses over a decade of accomplished and evolving expertise in human resources management, along with manufacturing and operations management. She earned an MBA, complemented by advanced marketing certifications. Demonstrating a track record of achievement, she excels in cultivating collaborative work environments and orchestrating transformative changes that lead to heightened productivity. With adeptness in business analysis, she has occupied senior managerial roles, showcasing her mastery. An engaged participant in professional circles, she maintains active memberships in SPHR and CHRP.

SOHM Inc. (OTC: SHMN), closed Thursday's trading session at $0.00105, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0005/$0.0017.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

GolfLync makes it possible for golfers to make connections in any season through a social media platform created by golfers for golfers

GolfLync's VCGs allow members to easily find local golf communities and public golf clubs in their area

As a revolutionary golf social media platform – GolfLync brings together the golfing community to foster relationships and build a greater sense of community

As the leaves fall and the seasons shift from warm to cool – new opportunities for comfortable golfing open up around the country. And golfing partners can change along with the seasons. If you enjoy a tee time with a cup of hot cider or a cold brew, the fall season is perfect in many locations for those looking to meet up for a few rounds on the course before the snow falls. These connections are now possible with GolfLync's innovative Virtual Golf Clubs(TM) ("VCGs"), allowing members to easily find local golf communities and public golf clubs in their area.

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.

 

Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News

chart

Diamond Lake Minerals Inc. (OTC: DLMI)

The QualityStocks Daily Newsletter would like to spotlight Diamond Lake Minerals Inc. (OTC: DLMI).

Diamond Lake Minerals' shares offer investors a traditional vehicle to gain exposure to the opportunity presented by regulated digital securities

The company's core objectives include generating substantial revenue streams, maintaining lean operations, ensuring profits and creating significant shareholder value

As of August 2023, outstanding shares of the company numbered slightly more than 23.5 million

The company has identified a roadmap of target acquisitions to fuel the growth and profitability of its business model

Diamond Lake Minerals (OTC: DLMI), a leading multi-strategy operating company specializing in developing and supporting digital assets and SEC-registered security tokens, today announced a significant milestone in its journey. The company has engaged Fruci & Associates II, PLLC as its PCAOB registered auditing firm for a comprehensive two-year audit, aligning with its strategy to enhance transparency, boost investor confidence, and support its planned uplisting to a senior national exchange.

"The engagement of Fruci & Associates exemplifies our dedication to responsible and transparent financial reporting," said Brian J. Esposito, CEO of Diamond Lake Minerals. "We believe that uplisting to a senior national exchange is an important step that will expand our reach and credibility, while facilitating participation with institutional investors. Fruci & Associates, with its commitment to investor protection, will be instrumental in helping us continue towards achieving our goal of ensuring the company's financial integrity."

To view the full press release, visit https://ibn.fm/8ielj

Diamond Lake Minerals Inc. (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

  • Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
  • Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
  • Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
  • Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
  • Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
  • IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
  • Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
  • Technology: DLMI plans to back pioneers driving the next tech revolution.
  • Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
  • Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
  • Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
  • Education: DLMI collaborates with platforms revolutionizing learning through tech.
  • Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
  • Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
  • TV: DLMI intends stakes in TV platforms innovating content delivery.
  • Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
  • Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
  • Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
  • IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
  • Data Management: DLMI seeks ventures optimizing data utilization and insights.
  • Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
  • Streaming: DLMI intends to back streaming platforms prioritizing user experience.
  • Real World Assets: DLMI eyes investments translating tangible assets into digital value.
  • Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
  • Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
  • Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
  • Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
  • Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
  • Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
  • Studio Production: DLMI’s vision includes support for studios transforming content creation.
  • Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
  • Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
  • Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
  • Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
  • Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
  • Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
  • Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
  • Space Economy: DLMI targets investments in ventures monetizing space exploration.
  • Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
  • Financial Technology: DLMI seeks partnerships modernizing financial transactions.
  • Gaming: DLMI aims to back game developers enhancing user immersion.
  • Travel: DLMI eyes collaborations transforming travel experiences through tech.
  • Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
  • Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
  • AI: DLMI seeks to support AI innovations humanizing tech interactions.
  • Esports: DLMI targets investments in platforms amplifying esports experiences.
  • Construction: DLMI plans to back ventures modernizing construction practices.
  • Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
  • Retail Tech: DLMI envisions collaborations digitizing retail experiences.
  • Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

Diamond Lake Minerals Inc. (OTC: DLMI), closed Thursday's trading session at $3.4125, off by 2.2206%, on 449 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$3.50.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

E-commerce was born with the advent of the internet more than two decades ago, and it revolutionized business on a global scale. The internet opened an entirely new avenue for trade and granted companies access to a massively expanded market, allowing e-commerce to reach almost 19% of all global retail sales in 2022. Although digital health has been around for quite a while now, major e-commerce players such as Amazon and Walmart began making major investments in the healthcare sector in the wake of the coronavirus pandemic. The pandemic revealed that people are willing to seek medical help online if the process is more convenient and requires minimal wait times compared to visiting a healthcare facility for in-person treatment. A recent report on ResearchAndMarkets.com has revealed that e-commerce is already reshaping the consumer healthcare field. E-commerce is poised to accelerate the global consumer healthcare industry's growth significantly, the report noted. Entities such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) look poised to benefit from the growth of healthcare e-commerce around the world as more people opt to obtain healthcare products and services online.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Thursday's trading session at $1.71, off by 5.1318%, on 8,029 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, presented virtually in a webcast presentation as part of of the Lytham Partners Fall 2023 Investor Conference. The company's president and CEO Joel Fruendt and CFO Tom Chesterman joined Lytham Partners Managing Partner Robert Blum to provide an overview of the company and its unique positioning in the market. "At SenesTech, we have a significant opportunity to create something special. It's why I joined the company in November of last year. We are addressing one of the world's most challenging problems – rodent control – through a completely different way than has ever been done before by addressing the root cause of the problem – reproduction," Fruendt said during the presentation. "The existing solutions' effectiveness, namely poisons, that are in the marketplace are limited by rats' reproduction rates, resistance and aversion as well well as the enhanced social and political limitations on the use of poison... As communities increasingly look to deploy sustainable, effective solutions, fertility control fits right in with that objective. Products that can be paradigm-changing don't come along very often but, when they do, they have an opportunity to change the way things have been done for generations, and at SenesTech, we can do that."

To view the full webcast, visit https://ibn.fm/Zdxrm

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest®

SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Thursday's trading session at $0.3655, off by 8.1427%, on 107,938 volume. The average volume for the last 3 months is 109,351 and the stock's 52-week low/high is $0.3111/$11.20.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical company, was featured in the most recent release of the Bell2Bell podcast series. During the segment, PaxMedia CEO and chair Howard Weisman and PaxMedica corporate communications representative Buzz Woods provided an overview of the company's latest accomplishments and future objectives with Bell2Bell host Stuart Smith. The trio discussed PaxMedia's pioneering work in novel anti-purinergic drug therapies ("APT") for neurologic conditions, specifically autism spectrum disorder ("ASD") along with the company's initiatives and visionary advancements in the novel APT therapies space.

The Bell2Bell Podcast is part of IBN's sustained effort to provide specialized content distribution via widespread syndication channels. "I've been in this industry for almost four decades now, and I've rarely seen a situation like autism spectrum disorder that's been so overlooked by the mainstream industry and so underserved by some of the entrepreneurs that could be entering the space," said PaxMedia CEO and chair Howard Weisman during the interview. "We are an entrepreneurial-driven company because we are entrepreneurs, and we are all scientists as well. This is a passion for us to be able to operate in this market in the first place, and it's a privilege to be able to help these families if we can who are suffering and need someone to step forward, and we plan to do that."

To view the full interview, visit https://ibn.fm/h2keq

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Thursday's trading session at $0.278, off by 14.4879%, on 1,440,708 volume. The average volume for the last 3 months is 1.017M and the stock's 52-week low/high is $0.20/$4.07.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, today announced that it has filed a preliminary proxy statement with the Securities and Exchange Commission (the "SEC") regarding a special stockholders' meeting to be held on Dec. 15, 2023, to authorize Mullen's board of directors to effect a reverse stock split of the company's common stock at an exchange ratio between 1-for-2 to 1-for-100. Mullen expects that the board's primary focus in determining whether or not to effectuate the reverse stock split will be the ability to obtain and maintain a continued price of at least $1.00 per share of its common stock on the Nasdaq Capital Market without effecting the reverse stock split. The reverse stock split will only be implemented if necessary to regain compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth a minimum $1.00 bid price. The board will determine the final split ratio after stockholder approval and would retain the authority to abandon the reverse stock split at any time or to delay or postpone it. The reverse stock split would not affect any stockholder's percentage ownership interests or proportionate voting power, except to the extent that it results in a stockholder receiving cash in lieu of fractional shares.

To view the full press release, visit https://ibn.fm/vcl1Z

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.2677, off by 22.2932%, on 67,914,553 volume. The average volume for the last 3 months is 111.439M and the stock's 52-week low/high is $0.2544/$137.25.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.